Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
歐康維視生物-B白內障術後炎症新藥臨床試驗反映安全有效

2024-04-15T  
歐康維視生物-B阿柏西普眼內注射溶液於內地完成III期臨床試驗

2024-04-08T  
《公司業績》歐康維視生物全年虧損收窄至3.8億人民幣

2024-03-22T  
《大行報告》大摩:現判斷中國生科板塊轉向仍尚早 但逆風減弱

2024-03-15T  
歐康維視生物OT-202II期臨床試驗達到主要終點 料啟動III期臨床試驗

2024-03-14T  
歐康維視生物-B出售EyePoint逾291萬股 套現5,666萬美元

2024-01-17T  
歐康維視生物OT-703獲批於香港上市

2023-12-21T  
歐康維視生物-B核心產品優施瑩獲納入國家醫保藥品目錄

2023-12-13T  
歐康維視生物-B治療白內障術後炎症新藥於內地完成臨床試驗患者入組

2023-11-30T  
歐康維視生物-B擬斥最多1億元回購股份

2023-11-29T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.